Gilead's Q2 preview: loss to reflect acquisition charges (GILD:NASDAQ)
· seekingalpha.com
Gilead (GILD) Q2 earnings may show a steep one-time loss from acquisition charges; watch HIV cash flow and oncology (Trodelvy) updates—read the preview.
Gilead Sciences (GILD) will report second-quarter results on Tuesday, with a likely steep loss driven by a one-time acquisition-related charge. Though the focus...